Cenzestotug Biosimilar Monoclonal Antibody (OX40) for Research

Cat No.: GMP-Bios-INN-1128

Anti-TNFRSF4/CD134/OX40 therapeutic antibody (Pre-made Cenzestotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cenzestotug (development code YH-002) is a monoclonal antibody targeting OX40 (TNFRSF4). It is developed by Eucure (Beijing) Biopharma for solid tumors. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1128-1mg 1mg 3090
GMP-Bios-INN-1128-10mg 10mg
GMP-Bios-INN-1128-100mg 100mg
GMP-Bios-INN-1128-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Cenzestotug biosimilar, Whole mAb, Anti-TNFRSF4/CD134/OX40 Antibody: Anti-CD134/OX40/TNFRSF4/Tumor necrosis factor receptor superfamily member 4 therapeutic antibody
INN Name Cenzestotug
Target TNFRSF4/CD134/OX40
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC